Jacobs Levy Equity Management, Inc Travere Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 863,088 shares of TVTX stock, worth $14.1 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
863,088
Previous 2,174,213
60.3%
Holding current value
$14.1 Million
Previous $37.9 Million
59.16%
% of portfolio
0.06%
Previous 0.15%
Shares
18 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
101MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$145 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$125 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$123 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$81.9 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$78.3 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.05B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...